- Home
- Publications
- Publication Search
- Publication Details
Title
Laboratory monitoring of hemophilia A treatments: new challenges
Authors
Keywords
-
Journal
Blood Advances
Volume 4, Issue 9, Pages 2111-2118
Publisher
American Society of Hematology
Online
2020-05-13
DOI
10.1182/bloodadvances.2019000849
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors
- (2020) Elena Barbon et al. EMBO Molecular Medicine
- The current state and future directions of RNAi-based therapeutics
- (2019) Ryan L. Setten et al. NATURE REVIEWS DRUG DISCOVERY
- Intrinsic differences between FVIII a mimetic bispecific antibodies and FVIII prevent assignment of FVIII ‐equivalence
- (2019) Nina C. Leksa et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays
- (2019) Joanne Adamkewicz et al. THROMBOSIS AND HAEMOSTASIS
- Marstacimab, a tissue factor pathway inhibitor neutralizing antibody, improves coagulation parameters of ex vivo dosed haemophilic blood and plasmas
- (2019) Sunita Patel‐Hett et al. HAEMOPHILIA
- Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study
- (2019) Steven W Pipe et al. Lancet Haematology
- Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: Phase 2 trial results
- (2019) Amy D. Shapiro et al. BLOOD
- Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine
- (2019) Gaia Spadarella et al. BLOOD REVIEWS
- A Molecular Revolution in the Treatment of Hemophilia
- (2019) John S.S. Butterfield et al. MOLECULAR THERAPY
- A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors
- (2019) Guy Young et al. BLOOD
- Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline
- (2019) P. Vincent Jenkins et al. HAEMOPHILIA
- Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
- (2018) Yesim Dargaud et al. HAEMATOLOGICA
- Prediction of individual factor VIII or IX level for the correction of thrombin generation in haemophilic patients
- (2018) P. Chelle et al. HAEMOPHILIA
- Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies
- (2018) K. Nogami et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab
- (2018) Yesim Dargaud et al. HAEMATOLOGICA
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
- (2018) Johnny Mahlangu et al. NEW ENGLAND JOURNAL OF MEDICINE
- New Therapies for hemophilia
- (2018) Angela C. Weyand et al. BLOOD
- New therapies using non-factor products for patients with hemophilia and inhibitors
- (2018) Keiji Nogami et al. BLOOD
- Advances in the Treatment of Hemophilia: Implications for Laboratory Testing
- (2018) Armando Tripodi et al. CLINICAL CHEMISTRY
- Assay challenges (and opportunities) with non-factor VIII therapies for Hemophilia A
- (2018) Maria M. Aleman et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia
- (2018) Pratima Chowdary INTERNATIONAL JOURNAL OF HEMATOLOGY
- Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy
- (2017) K. John Pasi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors
- (2017) Johannes Oldenburg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emerging Therapeutic Strategies in the Treatment of Hemophilia A
- (2017) Olivier Christophe et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies
- (2017) Stefan Tiefenbacher et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
- (2017) Keiko Esaki et al. THROMBOSIS AND HAEMOSTASIS
- Discrepancies between one stage assay and chromogenic substrate assay in patients treated with recombinant or plasma-derived FVIII and usefulness of a specific standard in ReFacto AF®-treated patients
- (2016) C. Pouplard et al. HAEMOPHILIA
- A critical appraisal of one-stage and chromogenic assays of factor VIII activity
- (2016) F. Peyvandi et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Targeting TFPI for hemophilia treatment
- (2016) Julie A. Peterson et al. THROMBOSIS RESEARCH
- A first-in-human phase 1 study of ACE910, a novel factor VIII-mimetic bispecific antibody, in healthy subjects
- (2015) N. Uchida et al. BLOOD
- One-stage vs. chromogenic assays in haemophilia A
- (2015) Joachim J. Potgieter et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- New insights into the biology of tissue factor pathway inhibitor
- (2015) S. A. Maroney et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial
- (2015) P. Chowdary et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia
- (2015) Alfica Sehgal et al. NATURE MEDICINE
- Bleeding phenotype in carriers of haemophilia A does not correlate with thrombin generation
- (2014) A. Olsson et al. HAEMOPHILIA
- Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives
- (2013) G. Young et al. BLOOD
- Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
- (2013) A. Muto et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
- (2012) I. Hilden et al. BLOOD
- Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex
- (2012) R. Marlu et al. HAEMATOLOGICA
- Value assignment of the WHO 8th International Standard for factor VIII, concentrate (07/350)
- (2012) S. RAUT et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- The phenotypic and genetic assessment of antithrombin deficiency
- (2011) P. C. COOPER et al. International Journal of Laboratory Hematology
- Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316)
- (2011) A. R. HUBBARD et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Severe hemophilia with mild bleeding phenotype: molecular characterization and global coagulation profile
- (2010) E. SANTAGOSTINO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started